Genolution Presents Exosome and Liquid Biopsy Technologies at North American Nephrology Conference

Genolution, a company specializing in green biotechnology, said on October 26 that it had participated in ASN Kidney Week 2026, a nephrology conference held in Denver, Colorado, and presented its achievements in exosome and liquid biopsy technologies.

Genolution's booth at ASN Kidney 2026, held in Denver, Colorado, from the 21st to the 25th (local time). / Photo by Genolution

At the conference, held from October 21 to 25 (local time), Genolution operated its own booth and held business-to-business (B2B) partnership meetings with researchers from around the world and multinational healthcare companies.

On October 24, Dr. Cho Byungsoo, a clinical expert in kidney disease, personally presented a poster. He presented the results of collaborative research that identified key biomarkers clearly distinguishing IgA nephropathy from end-stage renal disease (ESRD), using EGCG-based automated concentration technology for extracellular vesicles (EVs).

The company plans to target the liquid biopsy and exosome isolation markets with its automated “end-to-end workflow” solution, which underpinned the research. Its strategy is to secure a strong competitive advantage through the lock-in effect of its proprietary automation technology, which covers everything from the separation and extraction of liquid biopsy samples, such as urine, to companion diagnostics.

A Genolution representative said, “Our participation in ASN 2026 will demonstrate to the global market that we have successfully expanded our unrivaled automated nucleic acid extraction technology into the fields of exosomes and liquid biopsy. As a key driver of a quantum leap in our precision medicine business, we will actively pursue business opportunities in global markets, including North America, to achieve both business growth and enhanced shareholder value.”

This content was produced with the assistance of AI translation services.